Triple Hair Group Signs Licensing Agreement for South Korean Market with Mother’s Pharmaceutical
Licensing agreement grants Mother’s Pharmaceutical exclusive rights to sell Triple Hair’s Therapy-07 prescription drug in South Korea.
- Licensing agreement grants Mother’s Pharmaceutical exclusive rights to sell Triple Hair’s Therapy-07 prescription drug in South Korea.
- Triple Hair’s first licensing agreement represents strong validation of the science and the Company’s clinical program.
- MONTRÉAL, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Triple Hair Group Inc. (“Triple Hair” or the “Company”), a company specializing in the development of innovative treatments for alopecia, is pleased to announce that it has signed a licensing agreement with Mother’s Pharmaceutical, granting Mother’s Pharmaceutical exclusive rights to sell Triple Hair’s Therapy-07 prescription drug in South Korea.
- “We are proud to have signed this milestone licensing agreement for Therapy-07 with Mother’s Pharmaceutical, a growing pharmaceutical company with proven expertise in distributing and commercializing prescription products for hair loss in South Korea,” said Jean-Philippe Gravel, President and CEO of Triple Hair.